This site is intended for Healthcare professionals only.

Zydus Cadila gets USFDA nod to sell BP lowering drug

Zydus Cadila gets USFDA nod to sell BP lowering drug

New Delhi: Cadila Healthcare on Saturday said its group firm Zydus Cadila has received the final approval from the US health regulator to market blood pressure medicine, Amlodipine, and Olmesartan Medoxomil tablets.

The nod by US Food and Drug Administration (USFDA) is for multiple strengths of the tablets 5mg/40mg; 10mg/20mmg and 10mg/40 mg, the company said in a BSE filing.

“The drug is indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure and will be manufactured at the group’s formulations manufacturing facility at Pharma SEZ Ahmedabad,” Cadila Healthcare added.

The group has now more than 150 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of filing process in FY2003-04, it added.

The following two tabs change content below.
Ruby Khatun

Ruby Khatun

Ruby Khatun joined Medical Dialogue as Reporter in 2016. She covers all the business news in different categories. She also covers all the updates in Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a post graduate from Jamia Hamdard. She can be contacted at Contact no. 011-43720751

Source: PTI
0 comment(s) on Zydus Cadila gets USFDA nod to sell BP lowering drug

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted